You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-MAP3K7 (MAP3K7) Antibodies

Full name:
anti-Mitogen-Activated Protein Kinase Kinase Kinase 7 Antibodies (MAP3K7)
On www.antibodies-online.com are 182 Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7) Antibodies from 15 different suppliers available. Additionally we are shipping MAP3K7 Kits (10) and MAP3K7 Proteins (6) and many more products for this protein. A total of 217 MAP3K7 products are currently listed.
Synonyms:
B430101B05, C87327, MEKK7, si:ch211-225h9.1, TAK1, TGF1a, zgc:110612
list all antibodies Gene Name GeneID UniProt
MAP3K7 313121 P0C8E4
MAP3K7 6885 O43318
MAP3K7 26409 Q62073

Show all species

Show all synonyms

All available anti-MAP3K7 Antibodies

Go to our pre-filtered search.

Top referenced anti-MAP3K7 Antibodies

  1. Human Polyclonal MAP3K7 Primary Antibody for EIA - ABIN358291 : Ono, Ohtomo, Ninomiya-Tsuji, Tsuchiya: A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta. in Biochemical and biophysical research communications 2003 (PubMed)
    Show all 5 references for ABIN358291

  2. Human Polyclonal MAP3K7 Primary Antibody for EIA, IHC (p) - ABIN360354 : Takaesu, Surabhi, Park, Ninomiya-Tsuji, Matsumoto, Gaynor: TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. in Journal of molecular biology 2003 (PubMed)
    Show all 5 references for ABIN360354

  3. Human Polyclonal MAP3K7 Primary Antibody for DB, EIA - ABIN358312 : Smit, Baas, Kuipers, Korswagen, van de Wetering, Clevers: Wnt activates the Tak1/Nemo-like kinase pathway. in The Journal of biological chemistry 2004 (PubMed)
    Show all 5 references for ABIN358312

  4. Human Polyclonal MAP3K7 Primary Antibody for ELISA, WB - ABIN185640 : Omori, Matsumoto, Sanjo, Sato, Akira, Smart, Ninomiya-Tsuji: TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. in The Journal of biological chemistry 2006 (PubMed)
    Show all 2 references for ABIN185640

  5. Human Polyclonal MAP3K7 Primary Antibody for IHC, ELISA - ABIN1532056 : Mungall, Palmer, Sims, Edwards, Ashurst, Wilming, Jones, Horton, Hunt, Scott, Gilbert, Clamp, Bethel, Milne, Ainscough, Almeida, Ambrose, Andrews, Ashwell, Babbage, Bagguley, Bailey, Banerjee, Barker et al.: The DNA sequence and analysis of human chromosome 6. ... in Nature 2003 (PubMed)
    Show all 2 references for ABIN1532056

  6. Human Polyclonal MAP3K7 Primary Antibody for ELISA, WB - ABIN1532055 : Shibuya, Yamaguchi, Shirakabe, Tonegawa, Gotoh, Ueno, Irie, Nishida, Matsumoto: TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. in Science (New York, N.Y.) 1996 (PubMed)
    Show all 2 references for ABIN1532055

  7. Human Polyclonal MAP3K7 Primary Antibody for EIA, WB - ABIN500865 : Yamaguchi, Shirakabe, Shibuya, Irie, Oishi, Ueno, Taniguchi, Nishida, Matsumoto: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. in Science (New York, N.Y.) 1996 (PubMed)

More Antibodies against MAP3K7 Interaction Partners

Human Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7) interaction partners

  1. Polyubiquitination of Transforming Growth Factor beta-activated Kinase 1 (TAK1) at Lysine 562 Residue Regulates TLR4 (show TLR4 Antibodies)-mediated JNK (show MAPK8 Antibodies) and p38 MAPK (show MAPK14 Antibodies) Activation

  2. The data emphasize the central role of TAK1 in controlling signaling cascades and functional responses in primary neutrophils, making it a promising target for therapeutic intervention in view of the role of neutrophils in chronic inflammatory conditions.

  3. MiR (show MLXIP Antibodies)-377 is an important negative regulator of E2F (show E2F1 Antibodies) and MAP3K7/NF-kB signaling pathway in melanoma cells.

  4. the TAK1 signaling pathway may represent a suitable target to design new, antifibrotic therapies

  5. Findings indicate that SHIP2 (show INPPL1 Antibodies) is a regulator of lymphatic function in humans and that inherited mutations in the INPPL1 (show INPPL1 Antibodies) gene may act in concert with HGF (show HGF Antibodies), and likely MAP3K7, mutations to exacerbate lymphatic phenotypes.

  6. Data indicate that inhibition of TGF-beta (show TGFB1 Antibodies)-activated protein kinase (show CDK7 Antibodies) 1 (TAK1) reduces chemokine (C-C motif) receptor 7 (CCR7 (show CCR7 Antibodies)) expression.

  7. identify coordinate loss of MAP3K7 and CHD1 (show CHD1 Antibodies) as a unique driver of aggressive prostate cancer development

  8. Data indicate 4-substituted 1H-pyrrolo[2,3-b]pyridines as potent inhibitors against TGFbeta (show TGFB1 Antibodies)-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2 (show MAP4K2 Antibodies)).

  9. Ubc13 (show UBE2N Antibodies) was dispensable for transforming growth factor beta (TGFbeta (show TGFB1 Antibodies))-induced SMAD (show SMAD1 Antibodies) activation but was required for activation of non-SMAD (show SMAD1 Antibodies) signaling via TGFbeta (show TGFB1 Antibodies)-activating kinase 1 (TAK1) and p38 (show CRK Antibodies)

  10. Data show that the ECSIT (show ECSIT Antibodies) (evolutionarily conserved signaling intermediate in Toll (show TLR4 Antibodies) pathways) complex, including MEKK7 (TAK1) and TNF receptor-associated factor 6 (TRAF6 (show TRAF6 Antibodies)), plays a role in Toll-like receptor 4 (show TLR4 Antibodies) -mediated signals to activate NF-kappa B (show NFKB1 Antibodies).

Mouse (Murine) Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7) interaction partners

  1. TAK1 (show NR2C2 Antibodies) and IKK2 (show IKBKB Antibodies) are novel mediators of SCF (show KITLG Antibodies)-induced signaling and potential targets for c-Kit (show KIT Antibodies)-driven diseases.

  2. Polyubiquitination of Transforming Growth Factor beta-activated Kinase 1 (TAK1) at Lysine 562 Residue Regulates TLR4 (show TLR4 Antibodies)-mediated JNK (show MAPK8 Antibodies) and p38 MAPK (show MAPK14 Antibodies) Activation

  3. TAKI-induced cytotoxicity is cell context specific, and apoptosis observed in macrophages is dependent on the constitutive autocrine action of TNF-alpha (show TNF Antibodies) for RIP1 (show RALBP1 Antibodies) activation and ROS (show ROS1 Antibodies) production.

  4. These results suggest a crucial role for TAK1 (show NR2C2 Antibodies) for maintaining the survival of committed regulatory T cells under physiological conditions.

  5. A possible mechanism by which tomoregulin-1 (show TMEFF1 Antibodies) regulates the development of cardiac hypertrophy in TAC (show IL2RA Antibodies)-induced cardiac hypertrophy is through inhibiting TGFbeta (show TGFB1 Antibodies) non-canonical (TAK1 (show NR2C2 Antibodies)-JNK (show MAPK8 Antibodies)) pathways in the myocardium.

  6. findings demonstrate that GC resistance for TAK1 (show NR2C2 Antibodies) activation associated with TLR4 (show TLR4 Antibodies) engagement may be an important contributor to GC resistance in inflammatory disorders.

  7. TAK1 (show NR2C2 Antibodies) regulates osteoclastogenesis by integrating activation of NF-kappaB (show NFKB1 Antibodies) and derepression of NOTCH (show NOTCH1 Antibodies)/RBPJ (show RBPJ Antibodies) in myeloid cells through inhibition of NUMBL (show NUMBL Antibodies).

  8. Epithelium-specific Tak1 (show NR2C2 Antibodies):Smad4 (show SMAD4 Antibodies)- and Trim33 (show TRIM33 Antibodies):Smad4 (show SMAD4 Antibodies)-double mutants display reduced expression of Mmp13 (show MMP13 Antibodies) in palatal medial edge epithelial cells.

  9. TAK1 (show NR2C2 Antibodies) regulates hepatic lipid metabolism and tumorigenesis via the AMPK (show PRKAA1 Antibodies)/mTORC1 axis, affecting both autophagy and PPARalpha (show PPARA Antibodies) activity.

  10. Nef markedly activated TAK1 (show NR2C2 Antibodies) in M-CSF (show CSF1R Antibodies)-derived M2-MPhi but not in GM-CSF (show CSF2 Antibodies)-derived M1-MPhi.

MAP3K7 Antigen Profile

Antigen Summary

The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2\; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported.

Alternative names and synonyms associated with MAP3K7

  • mitogen activated protein kinase kinase kinase 7 (map3k7) antibody
  • mitogen activated protein kinase kinase kinase 7 (Map3k7) antibody
  • mitogen-activated protein kinase kinase kinase 7 (MAP3K7) antibody
  • mitogen-activated protein kinase kinase kinase 7 (Map3k7) antibody
  • B430101B05 antibody
  • C87327 antibody
  • MEKK7 antibody
  • si:ch211-225h9.1 antibody
  • TAK1 antibody
  • TGF1a antibody
  • zgc:110612 antibody

Protein level used designations for MAP3K7

mitogen-activated protein kinase kinase kinase 7 , tak1 , TGF-beta-activated kinase TAK1 , TGF-beta activated kinase 1 , TGF-beta-activated kinase 1 , transforming growth factor-beta-activated kinase 1 , mitogen activated protein kinase kinase kinase 7 , transforming growth factor beta-activated kinase 1

GENE ID SPECIES
553788 Danio rerio
313121 Rattus norvegicus
6885 Homo sapiens
26409 Mus musculus
529146 Bos taurus
100171454 Pongo abelii
Selected quality suppliers for anti-MAP3K7 (MAP3K7) Antibodies
Did you look for something else?